Please use this identifier to cite or link to this item: http://hdl.handle.net/11434/1044
Title: Reduction of proteinuria by rosiglitazone in non-diabetic renal disease.
Epworth Authors: Kincaid-Smith, Priscilla
Fairley, Kenneth
Other Authors: Farish, Stephen
Best, James
Proietto, Joseph
Keywords: Thiazolidinediones
Proteinuria
Hypoglycemic Agents
Diabetes Mellitus
Obesity
PPAR Gamma
Proliferator-Activated Receptors
Biomarkers
Urine
Blood Glucose
Metabolism
Body Mass Index
Dose-Response Relationship, Drug
Disease Progression
Administration & Dosage
Therapeutic Use
Insulin
Blood
Complications
Drug Therapy
Etiology
Treatment Outcome
Epworth HealthCare, Melbourne, Australia
Issue Date: Feb-2008
Publisher: Wiley
Citation: Nephrology (Carlton). 2008 Feb;13(1):58-62
Abstract: AIM: To investigate the effect of a thiazolidinedione on proteinuria in patients with non-diabetic renal disease. METHODS: In an open-label randomized cross-over study, 40 adults with chronic non-diabetic renal disease completed the study. In a random fashion, one group was treated for 4 months with 4 mg of rosiglitazone first followed by a 4-month period of standard treatment. The opposite order was used for the second group. RESULTS: Baseline urinary protein excretion rate was 1.45 g/24 h. On rosiglitazone, there was a drop of urinary protein level of 0.24 g/24 h (P=0.045). In contrast, there was a trend for proteinuria to increase during the control period (0.12 g/24 h, P=0.18). The urine protein level on rosiglitazone was lower than on usual treatment (0.36 g/24 h, P=0.002, 95% CI 0.15-0.58). There was a similar beneficial effect on systolic blood pressure which was reduced by rosiglitazone by 7.8 mmHg (P=0.006, 95% CI 2.6-13.1). Although average fasting glucose was only 5.8 mmol/L, there was a significant Spearman correlation between fasting glucose and a reduction in urinary protein levels (r=0.34, P=0.045). CONCLUSION: It is concluded that thiazolidinediones may have a role in the management of non-diabetic proteinuria of various aetiologies. In this study the average body mass index was 28.9 kg/m2. It will be important to repeat these studies in non-overweight subjects with non-diabetic proteinuria and in addition to trial maximal therapeutic doses of the thiazolidenedione.
URI: http://hdl.handle.net/11434/1044
DOI: 10.1111/j.1440-1797.2007.00903.x
PubMed URL: https://www.ncbi.nlm.nih.gov/pubmed/18199105
ISSN: 1440-1797
1320-5358
Journal Title: Nephrology
Type: Journal Article
Affiliated Organisations: Faculty Education Unit, Faculty of Medicine, Dentistry and Health Sciences
Department of Medicine, St Vincent's Hospital
Department of Medicine, Austin Health – Repatriation Hospital, Heidelberg, Victoria 3081, Australia.
University of Melbourne, Melbourne, Victoria, Australia
Type of Clinical Study or Trial: Crossover Design
Appears in Collections:UroRenal, Vascular

Files in This Item:
There are no files associated with this item.


Items in EKB are protected by copyright, with all rights reserved, unless otherwise indicated.